{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:51:15Z","timestamp":1789386675625,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,1,20]],"date-time":"2013-01-20T00:00:00Z","timestamp":1358640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00296-013-2671-x","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T08:36:38Z","timestamp":1358584598000},"page":"1855-1864","source":"Crossref","is-referenced-by-count":28,"title":["The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation"],"prefix":"10.1007","volume":"33","author":[{"given":"Ozden","family":"Ar\u0131soy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemal","family":"Bes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Cifci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Sercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Soy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,20]]},"reference":[{"key":"2671_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379\u20131390","journal-title":"Lancet"},{"key":"2671_CR2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/RHU.0b013e3181f3bfba","volume":"16","author":"O Ortancil","year":"2010","unstructured":"Ortancil O, Konuk N, May H, Sanli A, Ozturk D, Ankarali H (2010) Psychological status and patient-assessed health instruments in ankylosing spondylitis. J Clin Rheumatol 16:313\u2013316","journal-title":"J Clin Rheumatol"},{"key":"2671_CR3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1790060109","volume":"6","author":"JH Barlow","year":"1993","unstructured":"Barlow JH, Macey SJ, Struthers GR (1993) Gender, depression and ankylosing spondylitis. Arthritis Care Res 6:45\u201351","journal-title":"Arthritis Care Res"},{"key":"2671_CR4","first-page":"613","volume":"27","author":"A Zink","year":"2000","unstructured":"Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. J Rheumatol 27:613\u2013622","journal-title":"J Rheumatol"},{"key":"2671_CR5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/rheumatology\/kel115","volume":"45","author":"J Martindale","year":"2006","unstructured":"Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA (2006) Disease and psychological status in ankylosing spondylitis. Rheumatology 45:1288\u20131293","journal-title":"Rheumatology"},{"key":"2671_CR6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.biopsych.2005.05.001","volume":"58","author":"DL Evans","year":"2005","unstructured":"Evans DL, Charney DS, Lewis L et al (2005) Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58:175\u2013189","journal-title":"Biol Psychiatry"},{"key":"2671_CR7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","volume":"27","author":"CL Raison","year":"2006","unstructured":"Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24\u201331","journal-title":"Trends Immunol"},{"key":"2671_CR8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/157339510791823835","volume":"6","author":"BE Leonard","year":"2010","unstructured":"Leonard BE (2010) The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 6:205\u2013212","journal-title":"Curr Immunol Rev"},{"key":"2671_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pnpbp.2004.11.003","volume":"29","author":"OJ Schiepers","year":"2005","unstructured":"Schiepers OJ, Wichers MC, Maes M (2005) Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29:201\u2013217","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2671_CR10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.2001.tb05827.x","volume":"933","author":"R Dantzer","year":"2001","unstructured":"Dantzer R (2001) Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933:222\u2013234","journal-title":"Ann N Y Acad Sci"},{"key":"2671_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/157488606776930562","volume":"1","author":"SB Patten","year":"2006","unstructured":"Patten SB (2006) Psychiatric side effects of interferon treatment. Curr Drug Saf 1:143\u2013150","journal-title":"Curr Drug Saf"},{"key":"2671_CR12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.psyneuen.2007.10.008","volume":"33","author":"R Dantzer","year":"2008","unstructured":"Dantzer R, Capuron L, Irwin MR et al (2008) Identification and treatment of symptoms associated with \u0131nflammation in medically \u0131ll patients. Psychoneuroendocrinology 33:18\u201329","journal-title":"Psychoneuroendocrinology"},{"key":"2671_CR13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446\u2013457","journal-title":"Biol Psychiatry"},{"key":"2671_CR14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.neuroscience.2005.02.023","volume":"133","author":"JL Reynolds","year":"2005","unstructured":"Reynolds JL, Ignatowski TA, Sud R, Spengler RN (2005) An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 133:519\u2013531","journal-title":"Neuroscience"},{"key":"2671_CR15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00213-003-1566-z","volume":"170","author":"C Tuglu","year":"2003","unstructured":"Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E (2003) Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170:429\u2013433","journal-title":"Psychopharmacology"},{"key":"2671_CR16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","volume":"214","author":"JR Bradley","year":"2008","unstructured":"Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214:149\u2013160","journal-title":"J Pathol"},{"key":"2671_CR17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14712598.3.1.141","volume":"3","author":"J Braun","year":"2003","unstructured":"Braun J, Sieper J (2003) Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 3:141\u2013168","journal-title":"Expert Opin Biol Ther"},{"key":"2671_CR18","first-page":"507","volume":"29","author":"U Lange","year":"2000","unstructured":"Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation\/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 29:507\u2013511","journal-title":"Eur J Med Res"},{"key":"2671_CR19","doi-asserted-by":"crossref","first-page":"463e467","DOI":"10.1016\/S1297-319X(02)00431-1","volume":"69","author":"B Sonel","year":"2002","unstructured":"Sonel B, Tutkak H, Duzgun N (2002) Serum levels of IL-1 beta, TNF-alpha, IL-8, and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine 69:463e467","journal-title":"Joint Bone Spine"},{"key":"2671_CR20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.arcmed.2006.09.008","volume":"38","author":"CT Chou","year":"2007","unstructured":"Chou CT, Huo AP, Chang HN, Tsai CY, Chen WS, Wang HP (2007) Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Arch Med Res 38:190\u2013195","journal-title":"Arch Med Res"},{"key":"2671_CR21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10165-009-0230-9","volume":"20","author":"LD Kozaci","year":"2010","unstructured":"Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N (2010) Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol 20:34\u201339","journal-title":"Mod Rheumatol"},{"key":"2671_CR22","first-page":"45","volume":"1","author":"T Frech","year":"2007","unstructured":"Frech T (2007) Treatment of ankylosing spondylitis: focus on etanercept. Biologics 1:45\u201351","journal-title":"Biologics"},{"key":"2671_CR23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","volume":"126","author":"J Lin","year":"2008","unstructured":"Lin J, Ziring D, Desai S et al (2008) TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 126:13\u201330","journal-title":"Clin Immunol"},{"key":"2671_CR24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group","year":"2003","unstructured":"Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817\u2013824","journal-title":"Ann Rheum Dis"},{"key":"2671_CR25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","volume":"2","author":"LC Silva","year":"2010","unstructured":"Silva LC, Ortigosa LC, Benard G (2010) Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2:817\u2013833","journal-title":"Immunotherapy"},{"key":"2671_CR26","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/j.1572-0241.2008.02175.x","volume":"103","author":"EV Loftus","year":"2008","unstructured":"Loftus EV, Feagan BG, Colombel JF et al (2008) Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn\u2019s disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 103:3132\u20133141","journal-title":"Am J Gastroenterol"},{"key":"2671_CR27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1130-6343(08)72837-X","volume":"32","author":"LC Fern\u00e1ndez Lis\u00f3n","year":"2008","unstructured":"Fern\u00e1ndez Lis\u00f3n LC, V\u00e1zquez Dom\u00ednguez B, Luis Fern\u00e1ndez J, Moreno Alvarez P, Fruns Gim\u00e9nez I, Liso Rubio J (2008) Quality of life of patients with rheumatoid arthritis undergoing out-patient treatment with TNF inhibitors. Farm Hosp 32:178\u2013181","journal-title":"Farm Hosp"},{"key":"2671_CR28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.regg.2010.04.010","volume":"45","author":"GM Abalos-Medina","year":"2010","unstructured":"Abalos-Medina GM, Ruiz-Villaverde G, S\u00e1nchez-Cano D, Ruiz-Villaverde R, Oca\u00f1a-Peinado F, Villaverde-Guti\u00e9rrez C (2010) Functional level and quality of life in ankylosing spondylitis, pilot study after 16\u00a0weeks TNF blocker treatment. Rev Esp Geriatr Gerontol 45:331\u2013334","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"2671_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"S Tyring","year":"2006","unstructured":"Tyring S, Gottlieb A, Papp K et al (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 367:29\u201335","journal-title":"Lancet"},{"key":"2671_CR30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2036.2005.02535.x","volume":"22","author":"P Persoons","year":"2005","unstructured":"Persoons P, Vermeire S, Demyttenaere K et al (2005) The impact of major depressive disorder on the short- and long-term outcome of Crohn\u2019s disease treatment with infliximab. Aliment Pharmacol Ther 22:101\u2013110","journal-title":"Aliment Pharmacol Ther"},{"key":"2671_CR31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200207000-00001","volume":"8","author":"GR Lichtenstein","year":"2002","unstructured":"Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T (2002) Infliximab improves quality of life in patients with Crohn\u2019s disease. Inflamm Bowel Dis 8:237\u2013243","journal-title":"Inflamm Bowel Dis"},{"key":"2671_CR32","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3748\/wjg.v13.i14.2089","volume":"13","author":"IM Minderhoud","year":"2007","unstructured":"Minderhoud IM, Samsom M, Oldenburg B (2007) Crohn\u2019s disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 13:2089\u20132093","journal-title":"World J Gastroenterol"},{"key":"2671_CR33","author":"\u0130 Ertenli","year":"2010","unstructured":"Ertenli \u0130, Ozer S, Kiraz S et al (2010) Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int. doi: 10.1007\/s00296-010-1616-x","journal-title":"Rheumatol Int"},{"key":"2671_CR34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/187152809789352221","volume":"8","author":"M Berthold-Losleben","year":"2009","unstructured":"Berthold-Losleben M, Heitmann S, Himmerich H (2009) Anti-inflammatory drugs in psychiatry. Inflamm Allergy Drug Targets 8:266\u2013276","journal-title":"Inflamm Allergy Drug Targets"},{"key":"2671_CR35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00296-003-0432-y","volume":"25","author":"Y Akkoc","year":"2005","unstructured":"Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N (2005) A Turkish version of the Bath Ankylosing Spondylitis Disease Activity \u0130ndex: reliability and validity. Rheumatol Int 25:280\u2013284","journal-title":"Rheumatol Int"},{"key":"2671_CR36","unstructured":"Aydemir \u00d6, G\u00fcvenir T, K\u00fcey L et al (1997). Reliability and validity of Turkish version of Hospital Depression and Anxiety Questionnaire. Turk Psik Derg 8:280\u2013287 (Turkish)"},{"key":"2671_CR37","unstructured":"Akdemir A, \u00d6rsel S, Da\u011f I et al (1996) Reliability and validity of Turkish version of Hamilton Depression Scale. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 4:251\u2013259 [Turkish]"},{"key":"2671_CR38","unstructured":"Yaz\u0131c\u0131 MK, Demir B, Tanr\u0131verdi N et al (1998) Interrater reliability and validity of Turkish version of Hamilton Anxiety Scale. T\u00fcrk Psikiyatri Dergisi 9:114\u2013117 [Turkish]"},{"key":"2671_CR39","unstructured":"Kocyi\u011fit H, Aydemir \u00d6, \u00d6lmez N et al (1992) Reliability and validity of Turkish version of Short Form 36 (SF-36). \u0130la\u00e7 ve Tedavi Dergisi 12:102\u2013106 [Turkish]"},{"key":"2671_CR40","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00296-010-1381-x","volume":"31","author":"O Baysal","year":"2011","unstructured":"Baysal O, Durmus B, Ersoy Y et al (2011) Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheumatol Int 31:795\u2013800","journal-title":"Rheumatol Int"},{"key":"2671_CR41","first-page":"1","volume":"44","author":"I Eren","year":"2007","unstructured":"Eren I, Sahin M, Cure E et al (2007) Interactions between psychiatric symptoms and disability and quality of life in ankylosing spondylitis patients. Arch Neuropsychiatry 44:1\u20139","journal-title":"Arch Neuropsychiatry"},{"key":"2671_CR42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1461145702003103","volume":"5","author":"M Wichers","year":"2002","unstructured":"Wichers M, Maes M (2002) The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 5:375\u2013388","journal-title":"Int J Neuropsychopharmacol"},{"key":"2671_CR43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0306-9877(03)00207-X","volume":"61","author":"AM Myint","year":"2003","unstructured":"Myint AM, Kim YK (2003) Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypothesis 61:519\u2013525","journal-title":"Med Hypothesis"},{"key":"2671_CR44","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.npp.1301029","volume":"31","author":"CB Zhu","year":"2006","unstructured":"Zhu CB, Blakely RD, Hewlett WA (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacol 31:2121\u20132131","journal-title":"Neuropsychopharmacol"},{"key":"2671_CR45","unstructured":"Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2012) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch Gen Psychiatry 3:1\u201311. doi: 10.1001\/2013"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2671-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-013-2671-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2671-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T14:12:53Z","timestamp":1562595173000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-013-2671-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,20]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2671"],"URL":"https:\/\/doi.org\/10.1007\/s00296-013-2671-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,20]]}}}